Researchers have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal neurodegenerative condition. The treatment, which uses ...

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company at the forefront of precision genetic medicines with a market capitalization of $1.87 billion, is navigating a critical juncture in its ...

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal ...

By editing the polymers of discarded plastics, chemists at the Department of Energy's Oak Ridge National Laboratory have ...

When rice is in its flowering and grain-filling stages, it is more sensitive to high nighttime temperatures than high daytime ...

Simultaneous discoveries in art and science highlight humanity's shared creativity, problem-solving, and the ...

The biotech plans to use the funding to advance clinical testing of an epigenetic silencing therapy it hopes could treat ...

A Brandon scientist says the future of agricultural crop research in Canada will be focused on gene editing and trait study, ...

In BlueAllele Corp. v. Intellia Therapeutics, Inc., 2024 U.S. Dist. Lexis 222094 (D. Del. Dec. 9, 2024)1, the District of ...

Applied DNA Sciences, Inc. (NASDAQ: APDN) disclosed in an 8-K filing to the U.S. Securities and Exchange Commission that they had employed a company presentation for potential investor interactions.